The Top 5 Biosimilar Articles for the Week of April 19

Here are the top 5 biosimilar articles for the week of April 19, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 19, 2021.

Number 5: In the second portion of a 2-part series on a study from the independent research center NORC at University of Chicago, The Center for Biosimilars® took a look at how pricing transparency could aid uptake of biosimilars.

Number 4: Russian pharmaceutical company Pharmapark has obtained the Russian distribution rights for a bevacizumab biosimilar candidate (HD204) developed by Prestige BioPharma.

Number 3: Anticipating roughly $26 million in annual savings, British Columbia's public payer PharmaCare is switching patients away from originator Humira.

Number 2: Two pieces of legislation with the potential to improve biosimilar uptake are headed to President Joe Biden’s desk for his signature, following approvals in the House and Senate.

Number 1: New York Medicaid achieved 78% to 94% biosimilar utilization for 4 originator brands during a focused effort in 2019.

To read all of these articles and more, visit centerforbiosimilars.com.